How Cancer Immunotherapy is Getting Better

February 6, 2018

(TIME) – Last year, the Food and Drug Administration approved two new immunotherapies to treat certain leukemias and lymphomas. Now, in a study published in the New England Journal of Medicine, researchers detail who is most likely to benefit from the treatments, called CAR T cell therapy. CAR T cell therapy trains the body’s immune system to target and destroy cancer cells in the blood; scientists take people’s own immune cells (T cells) and genetically engineer them to seek out and destroy cancer cells.

Recommended Reading